Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
13 févr. 2024 13h29 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
19 janv. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
16 janv. 2024 16h27 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
HERE and Murata Manufacturing join forces to tackle traffic woes in Jakarta, Indonesia
05 déc. 2023 20h00 HE
|
HERE Technologies
HERE map and traffic data are integrated with Murata’s traffic counter system to help city authorities in Indonesia’s capital city Jakarta to improve traffic management ...
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
28 nov. 2023 07h42 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
02 nov. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
14 sept. 2023 14h59 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
HERE data chosen by majority of automakers for their EU intelligent speed assistance solution
05 sept. 2023 03h00 HE
|
HERE Technologies
More than 50 brands from 21 global automakers select the HERE ISA Map to comply with the EU Intelligent Speed Assistance regulation. HERE location data and software used in 180 million vehicles...
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
30 août 2023 16h41 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
PS2023: The Virtual Trip offers an opportunity to access a wide spectrum of sessions from Psychedelic Science 2023, the largest psychedelics conference in history.With a rolling release schedule,...
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
10 août 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada...